Antares Pharma (NASDAQ:ATRS)‘s stock had its “buy” rating reaffirmed by equities researchers at Raymond James in a research note issued on Thursday, AnalystRatings.com reports.
A number of other research analysts have also commented on the stock. Zacks Investment Research lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, August 10th. HC Wainwright reaffirmed a “buy” rating on shares of Antares Pharma in a report on Monday, August 10th. BidaskClub raised Antares Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, September 11th. LADENBURG THALM/SH SH restated a “buy” rating and issued a $7.00 target price on shares of Antares Pharma in a research note on Sunday, June 21st. Finally, Piper Sandler reiterated an “overweight” rating and set a $5.00 price target on shares of Antares Pharma in a research note on Sunday, June 21st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $5.63.
NASDAQ:ATRS traded up $0.14 during mid-day trading on Thursday, hitting $2.84. 1,188,733 shares of the company’s stock traded hands, compared to its average volume of 1,295,676. The firm has a market capitalization of $448.45 million, a price-to-earnings ratio of 71.02 and a beta of 1.24. The firm has a 50 day moving average of $2.77 and a two-hundred day moving average of $2.72. The company has a current ratio of 2.90, a quick ratio of 2.41 and a debt-to-equity ratio of 0.71. Antares Pharma has a 12 month low of $1.60 and a 12 month high of $5.13.
Several hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC lifted its position in shares of Antares Pharma by 28.5% during the 1st quarter. Aperio Group LLC now owns 25,433 shares of the specialty pharmaceutical company’s stock worth $60,000 after buying an additional 5,646 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Antares Pharma by 70.1% during the first quarter. Wells Fargo & Company MN now owns 304,328 shares of the specialty pharmaceutical company’s stock valued at $717,000 after acquiring an additional 125,440 shares during the period. AQR Capital Management LLC boosted its stake in shares of Antares Pharma by 780.3% in the 2nd quarter. AQR Capital Management LLC now owns 851,303 shares of the specialty pharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 754,597 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Antares Pharma by 1,615.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 325,096 shares of the specialty pharmaceutical company’s stock worth $767,000 after purchasing an additional 306,145 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Antares Pharma by 1.4% during the 1st quarter. Swiss National Bank now owns 300,700 shares of the specialty pharmaceutical company’s stock worth $710,000 after purchasing an additional 4,200 shares in the last quarter. Institutional investors own 42.96% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.